Abstract: The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or modification of biological activities of a growth and/or differentiation factor, a growth hormone or a cytokine. This invention also provides a wound-healing method, which comprises as an active ingredient a compound of the following formula (1) or formula (2) found to be active by the screening method.

Abstract: A hold-transfer system for extraction containers has a main body and a cassette detachable from the main body. The cassette has holding devices for holding extraction containers in an upright position, an endless traveling member carrying the holding devices arranged in a row, and a driving rotor and a driven rotor engaging the endless traveling member about perimeters thereof. The endless traveling member has rotatable support member for rotatably supporting the holding devices with lower portions of the holding devices protruding below the rotatable support members and accessible from beneath the cassette. The main body has a driving motor for driving the driving rotor and an identifying device, installed at a reading position relative to a specified position for an extraction, for identifying an identification mark associated with one of the extraction containers.

Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.

Abstract: The present invention relates to pyrimidine compounds represented by the formula ##STR1## (wherein X is a substituted or a cyclic amino group and Y is a substituted amino group or a substituted carbonyl group) or their pharmaceutically acceptable salts, and a therapeutic agent for neurological diseases comprising the compounds.These compounds are useful for treatment of various disorders in nervous systems since they are effective on growth of neurons and promotion of the formation and elongation of neutrites.

Abstract: This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.

Abstract: An immunity analysis apparatus for use with magnetic particles in which a sample is transferred to a reaction vessel and the reaction vessel is conveyed past several devices for adding and agitating a magnetic particle solution, adding a stroma solution, absorbing the particles to an inner wall of the reaction vessels to remove the reaction solution, adding an enzyme labelling antibody solution, absorbing the particle on an inner wall a second time to remove the resulting solution, adding a stop solution, measuring the result, and cleaning the reaction vessels for a reuse. The device additionally has structure for agitating the magnetic particle reagent solution containers and moving a pipet arm independent of an L-shaped agitating rod arm during a portion of its movement to supply the reaction vessels with the magnetic particle solution.

Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.

Abstract: A pharmaceutical composition comprising a pyrimidine represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom, an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, an alkoxycarbonylmethyl group having 3 to 5 carbon atoms, a 3,4-dimethoxybenzoyl group or a 3,4-methylenedioxybenzyl group,R.sup.2 represents a hydrogen atom, an amino group, a monoalkylamino group having 1 to 4 carbon atoms, an alkoxy group having 1 to 5 carbon atoms or an alkoxycarbonyl group having 2 to 4 carbon atoms,R.sup.3 represents a hydrogen atom, an alkoxycarbonyl group having 2 to 4 carbon atoms, a dialkylaminocarbonyl group having 1 to 9 carbon atoms in each alkyl moiety, an alkoxy group having 1 to 5 carbon atoms, or a hydroxyethyl group, R.sup.2 and R.sup.3, together with the carbon atoms to which they are bonded, may form a 5- to 7-membered carbocyclic ring or a heterocyclic ring having N, O or S as the hetero atom, and R.sup.